NCT03315975

Active Not RecruitingPhase 4

Flu Vaccine Responses in the Setting of Melanoma Treatment

University of Pennsylvania Source

University of Pennsylvania

ClinicalTrials.gov

Compare

Other study identifiers

Sponsor study identifier

826207

Study Type

interventional

Estimated enrollment

40

Locations

1 country

Sites

1

Timeline

Study Start

October 20, 2017

Actual (reported)

Primary Completion

July 1, 2026

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Study Completion

July 1, 2026

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Brief Summary

Influenza vaccination is indicated for all adults, but the immunogenicity of vaccination has not been assessed in all situations. We are conducting a prospective unblinded study of influenza vaccine recipients.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: active not recruiting
Estimated enrollment: 40 participants
Study completion date: July 1, 2026
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
October 16, 2017
Actual (reported)
First Posted
October 20, 2017
Actual (reported)
Study Start
October 20, 2017
Actual (reported)
Primary Completion
July 1, 2026
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
July 1, 2026
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.

Last Updated: August 19, 2025
Status Verified: August 2025
Last Update Submitted: August 13, 2025

Conditions

Viral Vaccines

Keywords

Influenza vaccine

Outcome Measures

Primary Outcomes (1)

Neutralizing antibody response
The neutralizing antibody titer will be assessed by measurement of the hemagglutinin-inhibition titer before and after influenza vaccination in order to determine the seroconversion rate. The late blood draw may occur between days 21-42 following vaccination.
21-42 days

Study Arms (1)

Influenza vaccination cohort

EXPERIMENTAL

Subjects will receive one dose of seasonal quadrivalent inactivated influenza vaccine intramuscularly for standard of care for prevention of influenza infection.

Biological: Inactivated influenza vaccine

Interventions

Inactivated influenza vaccineBiological

One dose of quadrivalent inactivated influenza vaccine

Influenza vaccination cohort

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

adults capable of providing consent
have a diagnosis of locally advanced or metastatic melanoma

You may not qualify if:

Sponsors & Collaborators

University of Pennsylvania
Otherlead

Study Sites (1)

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

MeSH Terms

Conditions

Influenza, Human

Condition Hierarchy (Ancestors)

Respiratory Tract InfectionsInfectionsOrthomyxoviridae InfectionsRNA Virus InfectionsVirus DiseasesRespiratory Tract Diseases

Study Officials

E. John Wherry, PhD
University of Pennsyvlania
PRINCIPAL INVESTIGATOR

Study Design

Study Type: interventional
Phase: phase 4
Allocation: NA
Masking: NONE
Purpose: BASIC SCIENCE
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

October 16, 2017

First Posted

October 20, 2017

Study Start

October 20, 2017

Actual (reported)

Primary Completion

July 1, 2026

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

NCT07177417

Characterizing the Human Airway Immune Response to FluMist Vaccination

Phase 4Recruiting

NCT01194297

Study of Live, Attenuated Influenza Vaccination in Preterm and Full-Term Infants

Phase 4Terminated

NCT03101462

Live Attenuated Influenza Vaccine (LAIV) Versus Trivalent Inactivated Influenza Vaccine in Healthy Adults 18-49 Years

Phase 4Completed

NCT02285998

Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age

Phase 3Completed

NCT02600585

Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults

Completed

NCT02500680

The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)

Phase 1Unknown

are allergic to influenza vaccination
have received influenza vaccination within the past 6 months
require prednisone, methotrexate, or other immunosuppressing medications
have HIV infection
have a history of solid organ or bone marrow transplant
require combination immunotherapy
are on other studies requiring blood draws that might exceed 450 mL total during the period of the influenza vaccine study

Contact the study team to confirm eligibility.

Study Completion

July 1, 2026

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Last Updated

August 19, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing: Will not share

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT03315975
Data provider: ClinicalTrials.gov
Source updated: 2025-08-19
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:20:30 UTC

Locations

US(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

Influenza vaccination cohort

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

Data Sharing

Source record

Locations